{"nctId":"NCT00419952","briefTitle":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","startDateStruct":{"date":"2007-02"},"conditions":["Asthma"],"count":742,"armGroups":[{"label":"Symbicort","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide/formoterol (SYMBICORT) pMDI"]},{"label":"Budesonide","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide HFA pMDI"]}],"interventions":[{"name":"Budesonide/formoterol (SYMBICORT) pMDI","otherNames":[]},{"name":"Budesonide HFA pMDI","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female, African American (self-reported), ≥12 years of age\n* Moderate to severe asthma requiring treatment with an inhaled corticosteroid\n* Diagnosis of asthma for at least 6 months\n\nExclusion Criteria:\n\n* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)\n* Any significant disease or disorder that may jeopardize a subject's safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Number of Asthma Exacerbations","description":"An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":"NA"},{"groupId":"OG001","value":"61","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Asthma Exacerbations","description":"Number of participants with at least 1 exacerbation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)","description":"QT interval corrected using the Fridericia formula \\[QTc (Frid)\\] - Change from baseline to end of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":null},{"groupId":"OG001","value":"-0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment","description":"Total ectopic ventricular (VE) beats - number of participants with shift from normal (\\<50) to high (≥50) from baseline to visit 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment","description":"Total ectopic supraventricular (VE) beats - number of participants with shift normal (\\<50) to high (≥50) from baseline to visit 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment","description":"Total ventricular runs - number of participants with shift normal (\\<1) to high (≥1) from baseline to week 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Diary Assessments - Rescue-free Day","description":"Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered \"no\" to having used rescue medication that day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.88","spread":null},{"groupId":"OG001","value":"10.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Diary Assessments - Symptom-free Day","description":"Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered \"no\" to having symptoms that day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":null},{"groupId":"OG001","value":"7.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Diary Assessments - Asthma-control Day","description":"Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered \"no\" to having symptoms and \"0\" to the use of rescue medication that day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.68","spread":null},{"groupId":"OG001","value":"11.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Onset of Effect Questionnaire (OEQ)","description":"Number of participants with positive response to Item 2 in questionnaire \"During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"Onset of Effect Questionnaire (OEQ)","description":"Number of participants with positive response to Item 5 in questionnaire \"During the past week, you were satisfied with how quickly you felt your study medication begin to work.\" The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of \"strongly agree\" or \"somewhat agree\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Expiratory Flow (PEF) in Morning","description":"Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.13","spread":null},{"groupId":"OG001","value":"19.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1)","description":"Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"-0.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Treatment Satisfaction Measure (ATSM)","description":"Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.99","spread":null},{"groupId":"OG001","value":"45.64","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":377},"commonTop":["Headache","Nasopharyngitis","Sinusitis","Viral Upper Respiratory Tract Infection","Oropharyngeal Pain"]}}}